- Home
- AACG vs RNXT Comparison
AACG vs RNXT Comparison
Compare AACG & RNXT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AACG
- RNXT
- Stock Information
- Founded
- AACG 1999
- RNXT 2012
- Country
- AACG China
- RNXT United States
- Employees
- AACG N/A
- RNXT N/A
- Industry
- AACG Other Consumer Services
- RNXT Biotechnology: Pharmaceutical Preparations
- Sector
- AACG Real Estate
- RNXT Health Care
- Exchange
- AACG Nasdaq
- RNXT Nasdaq
- Market Cap
- AACG 51.9M
- RNXT 44.0M
- IPO Year
- AACG N/A
- RNXT 2021
- Fundamental
- Price
- AACG $1.16
- RNXT $1.02
- Analyst Decision
- AACG
- RNXT Strong Buy
- Analyst Count
- AACG 0
- RNXT 2
- Target Price
- AACG N/A
- RNXT $7.50
- AVG Volume (30 Days)
- AACG 53.2K
- RNXT 441.7K
- Earning Date
- AACG 11-10-2025
- RNXT 11-13-2025
- Dividend Yield
- AACG N/A
- RNXT N/A
- EPS Growth
- AACG N/A
- RNXT N/A
- EPS
- AACG N/A
- RNXT N/A
- Revenue
- AACG $39,064,701.00
- RNXT $662,000.00
- Revenue This Year
- AACG N/A
- RNXT $2,895.35
- Revenue Next Year
- AACG N/A
- RNXT $313.04
- P/E Ratio
- AACG N/A
- RNXT N/A
- Revenue Growth
- AACG 15.19
- RNXT N/A
- 52 Week Low
- AACG $0.70
- RNXT $0.75
- 52 Week High
- AACG $2.58
- RNXT $1.69
- Technical
- Relative Strength Index (RSI)
- AACG 35.55
- RNXT 40.86
- Support Level
- AACG $1.15
- RNXT $0.98
- Resistance Level
- AACG $1.30
- RNXT $1.14
- Average True Range (ATR)
- AACG 0.12
- RNXT 0.08
- MACD
- AACG 0.01
- RNXT -0.01
- Stochastic Oscillator
- AACG 12.82
- RNXT 11.56
About AACG ATA Creativity Global
ATA Creativity Global is an international educational services company focused on providing quality learning experiences that cultivate and enhance students' creativity. The operating segments of the company are (i) Overseas art study services (ii) Other educational services and (iii) Other services. Majority of its revenue comes from Overseas art study services.
About RNXT RenovoRx Inc.
RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical need with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed to ensure precise therapeutic delivery to directly target the tumor while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.